JAGXHealthcare · BiotechnologyThe 1 Wall Street analysts covering Jaguar Health, Inc. hold a median 12-month price target of $263 — +83498.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 55 of 100 as at 10 Sept 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Jaguar Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (99): Smaller than most of the companies we track.
Momentum (2): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on JAGX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +83498.8% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 19 May 2025 | First Berlin | Initiates | Buy | $60 |
| 7 July 2021 | Cantor Fitzgerald | Initiates | Overweight | $5.00 |
| 25 Nov 2020 | Aegis Capital | Initiates | Buy | — |
| 25 Nov 2020 | H.C. Wainwright | Reiterates | Buy | — |
| 25 Nov 2020 | Ladenburg Thalmann | Initiates | Buy | — |
| 25 Nov 2020 | Rodman & Renshaw | Initiates | Buy | — |
| 18 Nov 2019 | H.C. Wainwright | Reiterates | Buy | — |
| 18 Nov 2019 | HC Wainwright & Co. | Reiterates | Buy | $10 → $3.00 |
| 12 Sept 2019 | Ladenburg Thalmann | Initiates | Buy | — |
| 11 July 2017 | Rodman & Renshaw | Initiates | Buy | — |
| 12 Nov 2015 | Aegis Capital | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. JAGX appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 11 Sept 2026, Jaguar Health, Inc. returned −99.6% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 75% of US stocks
Cheaper than 97% of US stocks
Cheaper than 89% of US stocks
Cheaper than 65% of US stocks
Higher than 4% of US stocks
Higher than 8% of US stocks
Higher than 15% of US stocks
Higher than 7% of US stocks
Higher than 5% of US stocks
Higher than 3% of US stocks
Higher than 11% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Jaguar Health, Inc. has a market value of $1.6M and an enterprise value of $14.4M.
Revenue in the twelve months to 30 June 2026: $27.8M. The latest quarter shrank 58.9% year on year.
Net income over the same four quarters: −$36.9M, a −132.9% net margin.
Free cash flow in the twelve months to 30 June 2026: −$6.7M.
Trailing P/E: 0.0×; forward P/E: −0.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Jaguar Health, Inc. employs 47 people — $591K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Jaguar Health, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Jaguar Health Inc. (NASDAQ:JAGX) shares traded lower Thursday morning as investors assessed the clinical development timeline for the company's rare pediatric disease pipeline following an operational update.
Why it matters — This news signals investor concern about the clinical development timeline for Jaguar Health's rare pediatric disease pipeline after an operational update.
Jaguar Health's Napo Pharmaceuticals announced that all randomized pediatric MVID patients in the pivotal crossover clinical trial of crofelemer have entered the single-blind extension phase to receive blinded doses of crofelemer, supporting longer-term safety and efficacy data. The trial remains ongoing at centers in the US, EU, and UAE, and continued treatment will support plans to file an NDA in mid-2027.
Why it matters — This progress keeps the crofelemer MVID program on track toward a planned 2027 NDA filing, an important regulatory milestone for JAGX shareholders.
Jaguar Health announced that its subsidiary Napo Pharmaceuticals is providing the company's crofelemer powder for oral solution for compassionate use to treat intestinal failure in an infant patient with congenital sodium diarrhea. The company remains focused on its global development program for crofelemer as adjunctive therapy for pediatric rare intestinal failure diseases, including microvillus inclusion disease, with plans to file an NDA for crofelemer in mid-2027.
Why it matters — This additional compassionate-use patient reinforces the ongoing development and real-world application of Jaguar's crofelemer program for rare intestinal failure diseases, which supports broader progress toward its planned regulatory filing.
Jaguar Health announced the initiation of the commercial launch of Neonorm Dog, a new non-prescription, plant-based product extending its Neonorm franchise beyond foals and calves to support normal stool consistency and GI fluid balance in dogs. The company expects to make the product available through Amazon and Chewy soon.
Why it matters — This launch expands Jaguar's product portfolio into the canine companion-animal market, potentially broadening its commercial reach beyond its existing production-animal franchise.
Seeking Alpha published the prepared remarks transcript from Jaguar Health's Q2 2026 earnings call. The item consists of the company's prepared remarks for that quarterly earnings discussion.
Why it matters — A JAGX watcher would care because the transcript provides the company's own commentary on its second-quarter 2026 performance and outlook.
The 1 Wall Street analysts covering Jaguar Health, Inc. have a median 12-month price target of $263, with estimates ranging from $263 to $263. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 1 analysts covering Jaguar Health, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Jaguar Health, Inc. 55 out of 100 across roughly 4,600 US stocks as at 10 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 10 Sept 2026, Jaguar Health, Inc. ranks 55 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (99 of 100).
No one can know that. What the data says: the median 12-month target from 1 analysts implies +83498.8% from the last close, and Ticker Nerd's factor model ranks Jaguar Health, Inc. 55 out of 100 as at 10 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Jaguar Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for JAGX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $263 to $263 over the next 12 months.
Jaguar Health, Inc. returned -99.6% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Jaguar Health, Inc. is a commercial-stage pharmaceuticals company focused on developing and commercializing plant-based gastrointestinal products for humans and animals.
The most recent item we track (Benzinga, 10 Sept 2026): "Jaguar Health Stock Slides Thursday: What's Happening?". Jaguar Health Inc. (NASDAQ:JAGX) shares traded lower Thursday morning as investors assessed the clinical development timeline for the company's rare pediatric disease pipeline following an operational update.
Jaguar Health, Inc. is a commercial-stage pharmaceuticals company focused on developing and commercializing plant-based gastrointestinal products for humans and animals. Its current business is organized around two segments, Human Health and Animal Health, covering prescription and non-prescription products for conditions such as chronic diarrhea, bowel urgency, and related gastrointestinal distress. The company’s human portfolio includes therapies for HIV-related diarrhea and other gastrointestinal indications, while its animal health activities target companion and production animals with digestive health needs. Jaguar Health also works through its subsidiaries to support proprietary products derived from sustainably sourced botanical ingredients. Headquartered in San Francisco, California, Jaguar Health plays a specialized role in the pharmaceutical market by addressing gastrointestinal disorders across both human and veterinary care.
CEO Ms. Lisa A. Conte · 47 employees · United States · https://jaguar.health
